COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,686 Articles (22,913 medRxiv, 8,773 bioRxiv)

Most recent first Previous |  Page 1695: Articles 16941-16950  | Next

COVIDOUTCOME - Estimating COVID Severity Based on Mutation Signatures in the SARS-CoV-2 Genome
Nagy, A., Ligeti, B., Szebeni, J., Pongor, S., Gyorffy, B.
10.1101/2021.04.01.438063 — Posted: 2021-04-02
Discovery and in-vitro evaluation of potent SARS-CoV-2 entry inhibitors
Acharya, A., Pandey, K., Thurman, M., Klug, E., Trivedi, J., Lorson, C. L., Singh, K., Byrareddy, S. N.
10.1101/2021.04.02.438204 — Posted: 2021-04-02
An immunoinformatics approach to study the epitopes contributed by Nsp13 of SARS-CoV-2
Kumar, S., Azad, G. K.
10.1101/2021.04.02.438155 — Posted: 2021-04-02
SARS-CoV-2 B.1.1.7 infection of Syrian hamster does not cause more severe disease and is protected by naturally acquired immunity
Nunez, I. A., Lien, C. Z., Selvaraj, P., Stauft, C. B., Liu, S., Starost, M., Wang, T.
10.1101/2021.04.02.438186 — Posted: 2021-04-02
A high-throughput fluorescence polarization assay to discover inhibitors of arenavirus and coronavirus exoribonucleases
Hernandez Tapia, S. G., Feracci, M., De Jesus, C. T., El-Kazzi, P., Kaci, R., Garlatti, L., Decroly, E., Canard, B., Ferron, F., Alvarez, K.
10.1101/2021.04.02.437736 — Posted: 2021-04-02
One dose of COVID-19 nanoparticle vaccine REVC-128 provides protection against SARS-CoV-2 challenge at two weeks post immunization
Gu, M., Torres, J. L., Greenhouse, J., Wallace, S., Chiang, C.-I., Jackson, A. M., Porto, M., Kar, S., Li, Y., Ward, A. B., Wang, Y.
10.1101/2021.04.02.438218 — Posted: 2021-04-02
A realistic touch-transfer method reveals low risk of transmission for SARS-CoV-2 by contaminated coins and bank notes
Todt, D., Meister, T. L., Tamele, B., Howes, J., Paulmann, D., Becker, B., Brill, F. H., Wind, M., Schijven, J., Mhlekude, B., Goffinet, C., Krawczyk, A., Steinmann, J., Pfaender, S., Brueggemann, Y., Steinmann, E.
10.1101/2021.04.02.438182 — Posted: 2021-04-02
Qualitatively distinct modes of Sputnik V vaccine-neutralization escape by SARS-CoV-2 Spike variants
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Vilardo, A. E., Edelstein, A., Perandones, C., Kamil, J. P., Lee, B.
10.1101/2021.03.31.21254660 — Posted: 2021-04-02 Discussion: Offsite
Fine-tuning the Spike: Role of the nature and topology of the glycan shield structure and dynamics of SARS-CoV-2 S
Harbison, A. M., Fogarty, C. A., Phung, T. K., Satheesan, A., Schulz, B. L., Fadda, E.
10.1101/2021.04.01.438036 — Posted: 2021-04-01
Analysis of glycosylation and disulfide bonding of wild-type SARS-CoV-2 spike glycoprotein
Zhang, S., Go, E. P., Ding, H., Anang, S., Kappes, J. C., Desaire, H., Sodroski, J. G.
10.1101/2021.04.01.438120 — Posted: 2021-04-01

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).